NCT06493045View on ClinicalTrials.gov

First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

May 16, 2024

Primary Completion Date

February 7, 2025

Study Completion Date

February 7, 2025

Conditions
Not Determined
Interventions
DRUG

IRL757

IRL757 capsule

DRUG

Placebo

Placebo capsule

Trial Locations (1)

Unknown

CTC Clinical Trial Consultants AB, Uppsala University Hospital, Uppsala

Sponsors
All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

Integrative Research Laboratories AB

INDUSTRY

NCT06493045 - First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers | Biotech Hunter | Biotech Hunter